Silencing of Bruton’s tyrosine kinase (Btk) using short interfering RNA duplexes (siRNA)  by Heinonen, Juhana E. et al.
Silencing of Bruton’s tyrosine kinase (Btk) using short interfering
RNA duplexes (siRNA)
Juhana E. Heinonena;b, C.I. Edvard Smitha;, Beston F. Norea;
aClinical Research Center (CRC), KFC-Novum, Karolinska Institutet, Huddinge University Hospital, SE-141 86 Huddinge, Sweden
bDepartment of Biochemistry and Food Chemistry, University of Turku, FIN-20014 Turku, Finland
Received 28 June 2002; revised 17 July 2002; accepted 31 July 2002
First published online 21 AUgust 2002
Edited by Masayuki Miyasaka
Abstract Tec family tyrosine kinases, Bruton’s tyrosine kinase
(Btk), Itk, Bmx, Tec, and Txk, are multi-domain proteins in-
volved in hematopoietic signaling. Here, we demonstrate that
human Btk protein can transiently be depleted using double-
stranded short RNA interference (siRNA) oligonucleotides.
Imaging and Western blotting analysis demonstrate that Btk
expression is down regulated in heterologous systems as well
as in hematopoietic lineages, following transfection or micro-
injection of Btk siRNA duplexes. The induction of histamine
release, a pro-in£ammatory mediator, in RBL-2H3 mast cells
was reduced by 20^25% upon Btk down regulation. Similar,
results were obtained when the Btk activity was inhibited using
the kinase blocker LFM-A13. These results demonstrate a di-
rect role of Btk for the e⁄cient secretion of histamine in allergic
responses. 4 2002 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Protein tyrosine kinases (PTKs) of the Tec family, Bruton’s
tyrosine kinase (Btk), Itk, Bmx, Tec and Txk, are expressed
di¡erentially in hematopoietic lineages and play a central role
in signaling through immunoreceptors, such as T-cell recep-
tor, B-cell receptor (BCR) and FcO receptor. In B-cells, Btk is
a central player in cytoplasmic B-cell signaling initiated by the
antigen receptor (BCR) [1]. Upon antigen engagement, the
receptor complexes, which contain multiple immunoreceptor
tyrosine-based activation motifs, are coupled to a cascade of
tyrosine phosphorylations initiated by cytosolic PTKs, which
belong to Src, Syk, Jak and Tec families (for recent review see
[1,2]). The importance of Tec family kinases was immediately
highlighted by the discovery of mutations in Btk in humans
diagnosed with X-linked agammaglobulinemia and in mice
with X-linked immunode¢ciency (Xid) [3^6]. Furthermore, ty-
rosine phosphorylations and membrane translocation of Btk
take place upon activation of mast cells by antigen/IgE-medi-
ated cross-linking of the FcORI receptor [7^10]. In mast cells,
Btk mutations lead to impairment in pro-in£ammatory cyto-
kine production [11], intracellular calcium in£ux and granule
exocytosis [12], induced by cross-linking of high-a⁄nity IgE
receptor on mast cells. Simultaneously, a vast number of sig-
naling molecules have been reported to be involved and take a
part in the signal transduction of Tec family kinases (for an
overview see [2,13,14]). Post-transcriptional gene silencing by
double-stranded RNA interference (RNAi) was ¢rst observed
from studies in Caenorhabditis elegans and Drosophila mela-
nogaster and was subsequently found in other organisms (for
review see [15,16]). The use of RNAi in mammalian studies
has only recently been established by introducing short inter-
ference (21 bp) duplex RNA (siRNA) [17,18].
In this study, we use the siRNA strategy for blocking Btk
expression in hematopoietic cells and to examine consequen-
ces of the loss-of-function. We have designed three di¡erent
siRNA duplexes targeted to di¡erent positions in the BTK
gene. We were able to block Btk expression in a variety of
cell types including human preB-cells and B-cells, mouse
B-cells and in rat RBL-2H3 mast cells.
2. Materials and methods
2.1. Construction of siRNA duplexes
The siRNA duplexes used in our study are designed according to
the guidelines described earlier [17^19]. For Btk and Bmx, the sequen-
ces were chosen to target identical sequences for both human and
mouse genes. The alignment procedure was as described earlier [13].
All siRNA duplexes were synthesized with 2 nt deoxythymidine
3P-overhangs (Xeragon, USA) as described by Elbashir et al. [19].
The cDNA-targeted region and the sequence of the siRNA duplexes,
for Btk, Bmx and enhanced green £uorescent protein (EGFP), are
as follows: Btk siRNA-1 (accession no. NM_000061 and L29788);
targeted region (cDNA): 1682-TTGGTAAACGATCAAGGAG-1700 ;
sense siRNA: 5P-UUGGUAAACGAUCAAGGAGUU; antisense
siRNA: UUAACCAUUUGCUAGUUCCUC-5P ; Btk siRNA-2;
targeted region (cDNA): 895-GGGAAAGAAGGAGGTTTCA-913 ;
sense siRNA: 5P-GGGAAAGAAGGAGGUUUCAUU; antisense
siRNA: UUCCCUUUCUUCCUCCAAAGU-5P ; Btk siRNA-3; tar-
geted region (cDNA): 518-GAAGCTTAAAACCTGGGAG-536 ; sense
siRNA: 5P-GAAGCUUAAAACCUGGGAGUU; antisense siRNA:
UUCUUCGAAUUUUCCACCCUC-5P ; Bmx siRNA (accession no.
NM_001721 and NM_009759); targeted region (cDNA): 943-AAAG-
AAGGAGCATTTATGG-961 ; sense siRNA: 5P-AAAGAAGGAGC-
AUUUAUGGUU; antisense siRNA: UUUUUCUUCCUCGUAA-
AUACC-5P ; EGFP siRNA (accession no. AF435433, as described in
[20]) ; targeted region (cDNA): 28-GGAGTTGTCCCAATTCTTG-46 ;
sense siRNA: 5P-GGAGUUGUCCCAAUUCUUGUU; antisense
siRNA: UUCCUCAACAGGGUUAAGAAC-5P.
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2.2. Transfections
HEK-293T, NIH-3T3, Cos-7 and rat mast cells RBL-2H3 were
cultured in Dulbecco’s modi¢ed Eagle’s medium (Gibco/BRL) and
WEHI-231, NALM-6, Ramos and Raji cells were cultured in RPMI
1640 (Gibco/BRL) as described earlier [10]. Hematopoietic cells were
transfected with siRNA using Oligofectamine (Invitrogen) in Opti-
MEM0 1 medium (Gibco/BRL) according to the manufacturer’s in-
structions. FuGENE6 (Roche) was used for transfection of HEK-
293T and NIH-3T3 cells with the Btk-EGFP plasmid. The Btk-
EGFP plasmid was described earlier [10]. After 48 h incubation cells
were ¢xed as described [21] and stained with an a⁄nity-puri¢ed anti-
Btk-SH3 polyclonal antibody [10] visualized with FITC-conjugated
donkey anti-rabbit IgG (Jackson Laboratories Inc.).
2.3. Immuno£uorescence and microinjections
NIH-3T3 cells were grown to 50% con£uency on 22 mm cover-slips
and were co-injected with 100 nM triplet siRNA duplexes and 100 ng/
Wl Btk-EGFP plasmid into the cytoplasm using an Eppendorf 5246
Microinjector. For injection marker, 1 Wg/Wl dextran-tetramethylrho-
damine 70 kDa (Molecular Probes) was used. After 24 h incubation
cells were ¢xed, stained and visualized as described earlier. [10].
2.4. Biochemical analysis of gene expression
Cellular protein lysates were resolved on SDS^PAGE and then
transferred to nitrocellulose membrane as described earlier [22]. The
protein expression was analyzed using monoclonal anti-Btk (Becton
Dickinson PharMingen) and monoclonal anti-L-actin (Sigma).
2.5. Histamine release assay
The mast cell line, RBL-2H3, was transfected with 100 nM triplet
siRNA duplexes. After 48 h cells were sensitized by anti-DNP IgE
(500 ng/ml for 12 h) and stimulated with 1 Wg/ml DNP^bovine serum
albumin (Sigma). The reaction was stopped on ice after 15 min in-
duction. The histamine release was determined using enzyme-linked
immunosorbent assay (ELISA) (IBL GmbH, Germany). For drug-
induced inhibition, RBL-2H3 cells were incubated with 100 WM Btk
inhibitor, LFM-A13 (K-cyano-L-hydroxy-L-methyl-N-(2,5-dibromo-
phenyl) propenamide) [23], 30 min prior to stimulation.
3. Results and discussion
3.1. Suppression of endogenous Btk by siRNA duplexes
We synthesized three di¡erent siRNA duplexes speci¢c for
Btk mRNA, the sites being conserved on both the human and
the mouse gene. In addition to Btk siRNA, we made siRNA
for EGFP as a control. In some experiments siRNA speci¢c
for Bmx, a non-expressed member of Tec family kinases in
B-cell and mast cell lineages, was used as an additional con-
trol. Initial experiments were performed in the rat mast cell
line RBL-2H3 (Fig. 1A). We observed that the Btk silencing
was moderate when each of these duplexes was applied sepa-
rately. However, when we combined all three siRNA duplexes
Fig. 1. Btk siRNA-mediated inhibition of endogenous Btk expression. A: E¡ect of Btk siRNA on endogenous Btk expression, targeted toward
three di¡erent sites (1^3) in the Btk coding region. Upper: the expression of Btk in RBL-2H3 cells was analyzed 48 h post-transfection of
siRNA duplexes 1^3 added separately or in triplet combination (¢nal concentration 100 nM). For control, expression of Btk in non-transfected
cells and in Bmx siRNA-transfected cells is visualized (lanes 1^2). Lower: the Btk expression was normalized to L-actin levels of total cell ex-
tracts. Western blot analysis of Btk and L-actin was performed as described in Section 2. B: Confocal images of endogenous Btk expression in
RBL-2H3 mast cells 48 h after transfection with triplet Btk siRNA duplexes. Cells were ¢xed and stained for Btk (FITC, green), nuclear DNA
(DAPI, blue) and cytoskeleton (probed with Alexa Fluor0 647 Phalloidin, Cy5, red) as described in Section 2.
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(hereafter referred to as triplet duplexes), the Btk silencing
was great, up to 90% (Fig. 1A), while Bmx siRNA (control)
did not have any e¡ect on the Btk expression pattern. Con-
sistent with the Western blot analysis (Fig. 1A), an impaired
endogenous Btk expression was observed with confocal mi-
croscopy images of RBL-2H3 cells following siRNA transfec-
tion (Fig. 1B). In agreement with Btk-EGFP localization [10],
when the a⁄nity-puri¢ed antiserum was used on Btk-EGFP-
transfected Cos-7 cells a mainly cytoplasmic distribution was
observed (data not shown). However, in the RBL-2H3 cells a
distinct punctuated staining pattern was also seen (Fig. 1B).
This perinuclear staining has been previously observed in dif-
ferent hematopoietic cells expressing endogenous Btk (unpub-
lished data). The origin of this subcellular pattern is not
known and the possibility existed that the antiserum cross-
reacted with a protein expressed in hematopoietic cells. If
this is the case, the siRNA silencing technology allowed us
to re-examine and validate previous Btk stainings. Indeed, the
cytoplasmic stainings and the dotted regions were similarly
suppressed upon treatment of the triplet Btk siRNA duplexes
(Fig. 1B). Together these data show the speci¢city of siRNA
silencing of endogenous Btk expression and how this speci¢c
inhibition can be used to address biological questions. Further
studies will be needed in order to characterize the nature of
the perinuclear dot-like distribution of Btk in hematopoietic
cells.
3.2. Btk silencing in heterologous cell systems
In order to characterize siRNA silencing further, we tran-
siently transfected the Btk-EGFP plasmid into HEK-293T
cells together with triplet Btk siRNA duplexes (Fig. 2A). Us-
ing the Btk speci¢c siRNA, we were able to detect the Btk-
GFP silencing in living cells, but not with the Bmx siRNA
duplexes (Fig. 2A). As shown in Fig. 2A, the expression of
Btk-EGFP was inhibited e⁄ciently by Btk and as well as by
Fig. 2. Silencing of Btk-EGFP fusion gene by Btk siRNA and EGFP siRNA duplexes. A: Confocal images of Btk-EGFP expression in transi-
ently transfected HEK-293T cells together with Bmx siRNA (non-speci¢c siRNA control), triplet Btk siRNA and EGFP siRNA. B: Confocal
images of Btk-EGFP expression in representative living NIH-3T3 cells following co-injection of Btk-EGFP plasmid, without and with triplet
Btk siRNA duplexes (¢nal concentration 100 nM). Dextran-tetramethylrhodamine 70 000 was used in order to identify injected cells. Cells were
photographed at identical exposure time by confocal microscopy at 48 h post-transfection as described in Section 2.
Table 1
E¡ect of siRNA duplexes on histamine release of IgE/antigen-stimu-
lated rat RBL-2H3 mast cells
RBL-2H3 cells Histamine secretiona
(% of control)
Control (antigen/IgE-stimulated) 100b
+Triplet Btk siRNA duplexes 77T 5.1
Control (antigen/IgE-stimulated) 100
+LFM-A13 76T 4.2
E¡ect of Btk siRNA-transfected cells or treated with Btk inhibitor
LFM-A13. The cells were cultured in six-well culture dishes (2 ml
medium), were transfected with 100 nM Bmx siRNA (control) or
100 nM triplet Btk siRNA duplexes or incubated with 100 WM
LFM-A13. Histamine secretions were analyzed by ELISA as de-
scribed in Section 2.
aResults are averages of at least three independent experiments,
each in duplicate.
bAbsolute concentrations of histamine secretion in control experi-
ments were 14.3 ng/ml medium.
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EGFP siRNA duplex. Moreover, we found no di¡erence in
the inhibition intensity of Btk-EGFP expression when we per-
form these experiments in Cos-7 cells (data not shown). In
another experiment, we co-injected the Btk-EGFP plasmid
with Btk triplet siRNA duplexes into NIH-3T3 cells (Fig.
2B), so as to follow the expression at the single cell level. In
this case, we found the silencing to be essentially complete in
the majority of cells.
3.3. Uptake and persistence of siRNA in hematopoietic cell
lines
As shown in earlier experiments the transfection of Btk
siRNA duplexes to adherent cells was very e¡ective, since
Btk expression was strongly down regulated. Therefore, we
investigated the ability of hematopoietic suspension cells to
take up siRNA duplexes using transient transfection protocols
similar to adherent cells. Indeed, hematopoietic cells were able
to take up siRNA duplexes using oligofectamine, allowing us
to study suppression of genes targeted by siRNA (Fig. 3A).
As indicated in Fig. 3A, the Btk suppression was lower and
less e⁄cient as compared to RBL cells, about 60^70% using
the Btk triplet siRNA duplexes in mouse B-cell lymphoma
WEHI-231 and human preB-cell NALM-6. Similar results
were observed with human Ramos and Raji B-cell lines
(data not shown). These results illustrate the use of siRNA
in order to silence endogenous genes in hematopoietic cells,
which generally are not easily transfectable, although trans-
fections e⁄ciency needs further improvement.
3.4. Synergistic e¡ects of Btk siRNA duplexes
In the present study, the Btk siRNA duplexes synthesized
against three conserved sites were shown to have di¡erential
silencing activity (Fig. 1A). As shown above, combining all
three Btk siRNA duplexes induced the highest suppression.
Therefore, we sought to examine the e⁄ciency of these siRNA
duplexes in combination of two (Fig. 3B). When the siRNA-1
was combined with siRNA-2 or siRNA-3, we observed a syn-
ergistic e¡ect (Fig. 3B). In a similar manner, we observed that
the combination of siRNA-2 and siRNA-3 induced more si-
lencing than each one separately. Thus, our data indicate that
when the relatively inactive siRNA-1 is combined with mod-
erately active siRNA-2 or siRNA-3, the silencing e¡ect was
enhanced, possibly due to an altered accessibility to the
mRNA secondary structure. However, as indicated in a recent
work the siRNA e⁄ciency could not be predicted prior to
examination [24].
3.5. Btk silencing and allergic responses in mast cells
To study the biological relevance of endogenous Btk sup-
pression by siRNA duplexes, we set out to investigate signal-
ing responses of RBL-2H3 mast cells. In FcORI-stimulated
cells, the histamine release was decreased by 20^25% when
Btk expression was down regulated by triplet Btk siRNA
duplexes (Table 1). To validate the speci¢city and accuracy
of our data, we compared siRNA down regulation to the Btk
kinase inhibitor LFM-A13 [23]. In the presence of LFM-A13,
we observed a similar level of inhibition in histamine secre-
tion, about 20^25% (Table 1). The results indicate that Btk
kinase activity is required for e⁄cient mast cell activation and
therefore possibly in£uences allergic responses. These obser-
vations support previous ¢ndings measuring IP3 production,
granule exocytosis and calcium in£ux in wild-type and/or Xid
and Btk-de¢cient mast cells [12]. In mice with disease gene
mutations compensatory mechanisms could potentially devel-
op over time. By using siRNA or kinase inhibitors (LFM-
A13) such an in£uence is minimized. Despite that the siRNA
transfection in hematopoietic cells is less e⁄cient as compared
to adherent cells, this work shows a simple strategy to selec-
tively impair expression.
In order to potentiate the e¡ect of siRNA in lymphocytes,
Fig. 3. Silencing of endogenous Btk in siRNA-transfected lymphocytes. A: Direct transfection of 100 nM triplet Btk siRNA duplexes into sus-
pension of mouse B-cells (WEHI-231) and human preB-cells (NALM-6). B: Synergistic suppression of Btk in RBL-2H3 cells using Btk siRNA
(1^3) duplexes. The ¢nal concentration of Btk siRNA duplexes used for transfections was kept at 100 nM. In control lanes, either EGFP
siRNA or Bmx siRNA duplexes were used.
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plasmid-based delivery [25,26] combined with a selectable
marker could be applied, or alternatively, the transfection
procedures for siRNA oligonucleotides could be further im-
proved. In a collaborative e¡ort, we are currently studying a
retrovirus siRNA hairpin vector system for stable and e⁄cient
‘knock-down’ of gene(s) in B-cells and T-cells. Since siRNA
silencing is e¡ective and speci¢c while keeping the cellular
proteome intact, the function of many signaling molecules
could be revealed, including the possibility to simultaneously
target multiple genes.
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